Charles Duncan
Stock Analyst at Cantor Fitzgerald
(4.45)
# 561
Out of 4,496 analysts
194
Total ratings
49.22%
Success rate
21.01%
Average return
Main Sectors:
47 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VNDA Vanda Pharmaceuticals | Initiates: Overweight | $11 | $6.11 | +80.03% | 2 | Jul 11, 2024 | |
| MNMD Mind Medicine (MindMed) | Reiterates: Overweight | n/a | $7.93 | - | 3 | Jun 21, 2024 | |
| CYBN Cybin | Reiterates: Overweight | n/a | $0.30 | - | 5 | Jun 21, 2024 | |
| CMPS COMPASS Pathways | Reiterates: Overweight | n/a | $7.30 | - | 4 | Jun 21, 2024 | |
| ATAI Atai Life Sciences | Reiterates: Overweight | n/a | $1.48 | - | 3 | Jun 21, 2024 | |
| ITCI Intra-Cellular Therapies | Reiterates: Overweight | $120 | $74.86 | +60.30% | 14 | Jun 14, 2024 | |
| BHVN Biohaven Pharmaceutical Holding Company | Reiterates: Overweight | n/a | $35.98 | - | 9 | May 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $43 → $48 | $24.83 | +93.31% | 1 | May 23, 2024 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Overweight | $37 | $17.75 | +108.45% | 14 | May 9, 2024 | |
| HRMY Harmony Biosciences Holdings | Reiterates: Overweight | $49 | $32.04 | +52.93% | 7 | Apr 12, 2024 | |
| PRTA Prothena Corporation | Reiterates: Overweight | n/a | $23.58 | - | 12 | Apr 10, 2024 | |
| NBIX Neurocrine Biosciences | Reiterates: Overweight | $155 | $145.69 | +6.39% | 6 | Apr 10, 2024 | |
| MRNS Marinus Pharmaceuticals | Reiterates: Overweight | $28 | $1.43 | +1,858.04% | 4 | Apr 10, 2024 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $180 | $109.01 | +65.12% | 3 | Apr 10, 2024 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $107 | $84.85 | +26.10% | 13 | Apr 10, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $13.58 | - | 5 | Apr 4, 2024 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Overweight | $34 | $16.94 | +100.71% | 7 | Mar 22, 2024 | |
| CERE Cerevel Therapeutics Holdings | Downgrades: Neutral | $38 → $45 | $42.90 | +4.90% | 2 | Dec 7, 2023 | |
| DNLI Denali Therapeutics | Assumes: Overweight | $85 → $35 | $21.46 | +63.09% | 5 | Oct 24, 2023 | |
| CRNX Crinetics Pharmaceuticals | Assumes: Overweight | $52 → $50 | $52.66 | -5.05% | 3 | Oct 24, 2023 | |
| CYTK Cytokinetics | Maintains: Overweight | $59 → $65 | $56.41 | +15.23% | 5 | Oct 9, 2023 | |
| SLDB Solid Biosciences | Initiates: Overweight | $5 | $8.22 | -39.17% | 1 | Sep 22, 2023 | |
| SEEL Seelos Therapeutics | Downgrades: Neutral | n/a | $0.55 | - | 7 | Sep 21, 2023 | |
| VXRT Vaxart | Reiterates: Overweight | $4 | $0.68 | +492.59% | 4 | Sep 7, 2023 | |
| LUCD Lucid Diagnostics | Reiterates: Overweight | $4 | $0.84 | +376.30% | 4 | Aug 22, 2023 | |
| XENE Xenon Pharmaceuticals | Reiterates: Overweight | $58 | $42.73 | +35.74% | 3 | Aug 22, 2023 | |
| LUMO Lumos Pharma | Reiterates: Overweight | $10 | $1.46 | +584.93% | 4 | Aug 22, 2023 | |
| KALV KalVista Pharmaceuticals | Reiterates: Overweight | $20 | $14.55 | +37.46% | 2 | Aug 22, 2023 | |
| BIVI BioVie | Reiterates: Overweight | $11 | $0.39 | +2,753.44% | 4 | Aug 22, 2023 | |
| CLNN Clene | Reiterates: Overweight | $80 | $4.33 | +1,747.58% | 5 | Aug 16, 2023 | |
| CRDL Cardiol Therapeutics | Reiterates: Overweight | $3 | $2.09 | +43.54% | 2 | Aug 14, 2023 | |
| AVXL Anavex Life Sciences | Downgrades: Neutral | $16 → $11 | $5.48 | +100.73% | 1 | Dec 6, 2022 | |
| FENC Fennec Pharmaceuticals | Upgrades: Overweight | $9 → $12 | $6.39 | +87.79% | 2 | Nov 22, 2022 | |
| CGTX Cognition Therapeutics | Initiates: Overweight | $12 | $1.84 | +552.17% | 1 | Sep 29, 2022 | |
| NVAX Novavax | Maintains: Overweight | $146 → $168 | $13.85 | +1,113.00% | 6 | Jun 8, 2022 | |
| ORMP Oramed Pharmaceuticals | Initiates: Overweight | $20 | $2.55 | +684.31% | 1 | Feb 18, 2022 | |
| VTVT vTv Therapeutics | Initiates: Overweight | $200 | $20.40 | +880.39% | 3 | Feb 18, 2022 | |
| BNOX Bionomics | Initiates: Overweight | $52 | $0.84 | +6,083.85% | 1 | Jan 10, 2022 | |
| OVID Ovid Therapeutics | Downgrades: Neutral | n/a | $1.02 | - | 1 | Apr 20, 2021 | |
| SAVA Cassava Sciences | Initiates: Overweight | n/a | $10.08 | - | 1 | Oct 23, 2020 | |
| INO Inovio Pharmaceuticals | Downgrades: Neutral | $372 → $144 | $10.07 | +1,329.99% | 5 | Sep 28, 2020 | |
| GERN Geron | Maintains: Overweight | n/a | $4.60 | - | 1 | Jun 1, 2020 | |
| HALO Halozyme Therapeutics | Reiterates: Overweight | n/a | $54.04 | - | 2 | May 4, 2020 | |
| CARA Cara Therapeutics | Reiterates: Overweight | n/a | $0.34 | - | 1 | Apr 22, 2020 | |
| CORT Corcept Therapeutics | Downgrades: Neutral | n/a | $33.88 | - | 3 | Feb 1, 2019 | |
| SGMO Sangamo Therapeutics | Upgrades: Overweight | n/a | $0.40 | - | 1 | Nov 15, 2017 | |
| ALT Altimmune | Initiates: Overweight | n/a | $6.28 | - | 1 | Oct 9, 2017 |
Vanda Pharmaceuticals
Jul 11, 2024
Initiates: Overweight
Price Target: $11
Current: $6.11
Upside: +80.03%
Mind Medicine (MindMed)
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.93
Upside: -
Cybin
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.30
Upside: -
COMPASS Pathways
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.30
Upside: -
Atai Life Sciences
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.48
Upside: -
Intra-Cellular Therapies
Jun 14, 2024
Reiterates: Overweight
Price Target: $120
Current: $74.86
Upside: +60.30%
Biohaven Pharmaceutical Holding Company
May 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $35.98
Upside: -
Alkermes
May 23, 2024
Maintains: Overweight
Price Target: $43 → $48
Current: $24.83
Upside: +93.31%
ACADIA Pharmaceuticals
May 9, 2024
Reiterates: Overweight
Price Target: $37
Current: $17.75
Upside: +108.45%
Harmony Biosciences Holdings
Apr 12, 2024
Reiterates: Overweight
Price Target: $49
Current: $32.04
Upside: +52.93%
Prothena Corporation
Apr 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $23.58
Upside: -
Neurocrine Biosciences
Apr 10, 2024
Reiterates: Overweight
Price Target: $155
Current: $145.69
Upside: +6.39%
Marinus Pharmaceuticals
Apr 10, 2024
Reiterates: Overweight
Price Target: $28
Current: $1.43
Upside: +1,858.04%
Jazz Pharmaceuticals
Apr 10, 2024
Reiterates: Overweight
Price Target: $180
Current: $109.01
Upside: +65.12%
Axsome Therapeutics
Apr 10, 2024
Reiterates: Overweight
Price Target: $107
Current: $84.85
Upside: +26.10%
Stoke Therapeutics
Apr 4, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.58
Upside: -
Catalyst Pharmaceuticals
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $16.94
Upside: +100.71%
Cerevel Therapeutics Holdings
Dec 7, 2023
Downgrades: Neutral
Price Target: $38 → $45
Current: $42.90
Upside: +4.90%
Denali Therapeutics
Oct 24, 2023
Assumes: Overweight
Price Target: $85 → $35
Current: $21.46
Upside: +63.09%
Crinetics Pharmaceuticals
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $52.66
Upside: -5.05%
Cytokinetics
Oct 9, 2023
Maintains: Overweight
Price Target: $59 → $65
Current: $56.41
Upside: +15.23%
Solid Biosciences
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $8.22
Upside: -39.17%
Seelos Therapeutics
Sep 21, 2023
Downgrades: Neutral
Price Target: n/a
Current: $0.55
Upside: -
Vaxart
Sep 7, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.68
Upside: +492.59%
Lucid Diagnostics
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.84
Upside: +376.30%
Xenon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $42.73
Upside: +35.74%
Lumos Pharma
Aug 22, 2023
Reiterates: Overweight
Price Target: $10
Current: $1.46
Upside: +584.93%
KalVista Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $20
Current: $14.55
Upside: +37.46%
BioVie
Aug 22, 2023
Reiterates: Overweight
Price Target: $11
Current: $0.39
Upside: +2,753.44%
Clene
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $4.33
Upside: +1,747.58%
Cardiol Therapeutics
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $2.09
Upside: +43.54%
Anavex Life Sciences
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $5.48
Upside: +100.73%
Fennec Pharmaceuticals
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $6.39
Upside: +87.79%
Cognition Therapeutics
Sep 29, 2022
Initiates: Overweight
Price Target: $12
Current: $1.84
Upside: +552.17%
Novavax
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $13.85
Upside: +1,113.00%
Oramed Pharmaceuticals
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $2.55
Upside: +684.31%
vTv Therapeutics
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $20.40
Upside: +880.39%
Bionomics
Jan 10, 2022
Initiates: Overweight
Price Target: $52
Current: $0.84
Upside: +6,083.85%
Ovid Therapeutics
Apr 20, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.02
Upside: -
Cassava Sciences
Oct 23, 2020
Initiates: Overweight
Price Target: n/a
Current: $10.08
Upside: -
Inovio Pharmaceuticals
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $10.07
Upside: +1,329.99%
Geron
Jun 1, 2020
Maintains: Overweight
Price Target: n/a
Current: $4.60
Upside: -
Halozyme Therapeutics
May 4, 2020
Reiterates: Overweight
Price Target: n/a
Current: $54.04
Upside: -
Cara Therapeutics
Apr 22, 2020
Reiterates: Overweight
Price Target: n/a
Current: $0.34
Upside: -
Corcept Therapeutics
Feb 1, 2019
Downgrades: Neutral
Price Target: n/a
Current: $33.88
Upside: -
Sangamo Therapeutics
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $0.40
Upside: -
Altimmune
Oct 9, 2017
Initiates: Overweight
Price Target: n/a
Current: $6.28
Upside: -